Endometrial cancer prognosis evaluation system incorporating molecular typing and immune scoring

Abstract

The invention relates to an endometrial cancer prognosis evaluation system (MIP scoring) based on molecular typing, immune scoring and pathological morphology diagnosis, which is used for judging the prognosis of endometrial cancer. The POLE mutation state is judged through sequencing, and four mismatched repair proteins and p53 are detected through an immunohistochemical method to determine molecular subtypes; the expression of VISTA in tumor interstitial immune cells is detected by an immunohistochemical method, and immune scoring is carried out; the histological level and lymph-vascular space invasion (LVSI) of the tumor are judged by observing pathological morphology under the microscope; and endowing of recurrence risk scores is conducted correspondingly. The prognostic evaluation system can effectively distinguish recurrence and death risks of endometrial cancer.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the prognosis of endometrial cancer. Background technique [0002] Endometrial cancer is a relatively common gynecological malignancy. In my country, its incidence rate is about 60 / 100,000, and its mortality rate is about 20 / 100,000. The incidence rate is on the rise. In 2015, there were more than 60,000 new cases and more than 20,000 deaths in China. The most common treatment for endometrial cancer is mainly surgery. According to the postoperative pathological report, those with high risk factors may be combined with postoperative brachytherapy, external pelvic radiotherapy or chemotherapy as adjuvant therapy. Pathological diagnosis is the main basis for postoperative adjuvant therapy. In the 2014 edition of the "WHO Histological Classification of Tumors of Female Reproductive Organs", endometrial cancer is divided into nine categories, namely, endometrioid carcinoma, serous carcino...

AI Technical Summary

Problems solved by technology

[0006] TCGA endometrial cancer molecular typing is proposed based on high-throughput deep sequencing. High-throughput sequencing has high economic costs and takes a long time, which will limit the clinical application of molecular typing.

Although the TCGA alternative typing scheme proposed by later scholars has been proved to be effective by multiple teams, neither the TCGA typing nor the alternative typing can effectively distinguish the prognosis of 60%–70% of dMMR types and NSMP

Images